Survival has become the gold standard for determining the relative effectiveness of chemotherapy regimens in phase III clinical trials and is measured generally as the median survival. Response could be a surrogate for survival in evaluating clinical trials for chemotherapy, but it has become a controversial measurement parameter because of the quantitative variability in measurement and the fact that differences in response rates are not commonly translated into differences in survival. However, if response is indeed a determinant of survival, the median survival (the point at which 50% of the patients are alive) will not be impacted because response rates (RR) for most advanced cancers are less than 50%. Nonetheless, a survival benefit has been identified for tumors in which response rates are 50% or less in 4 phase III randomized trials; 2 in breast cancer (a high response-rate tumor) also show significant differences in survival. These data would imply that factors other than tumor response could be operative in influencing survival. It is a categorical truth that "responders" live longer than "nonresponders," but the response and survival relationship is complex and both parameters are important in clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.coc.0000135344.25259.99 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A whole-body imaging technique for tumor-specific diagnostics and screening of B7-H3-targeted therapies.
J Clin Invest
January 2025
Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, China.
Background: B7-H3 or CD276 is notably overexpressed in various malignant tumor cells in humans, with extremely high expression rates. The development of a radiotracer that targets B7-H3 may provide a universal tumor-specific imaging agent and allow the noninvasive assessment of the whole-body distribution of B7-H3-expressing lesions.
Methods: We enhanced and optimized the structure of an affibody (ABY) that targets B7-H3 to create the radiolabeled radiotracer [68Ga]Ga-B7H3-BCH, and then, we conducted both foundational experiments and clinical translational studies.
Use of Machine Learning to Predict Individual Postprandial Glycemic Responses to Food Among Individuals With Type 2 Diabetes in India: Protocol for a Prospective Cohort Study.
JMIR Res Protoc
January 2025
Decipher Health, Delhi, India.
Background: Type 2 diabetes (T2D) is a leading cause of premature morbidity and mortality globally and affects more than 100 million people in the world's most populous country, India. Nutrition is a critical and evidence-based component of effective blood glucose control and most dietary advice emphasizes carbohydrate and calorie reduction. Emerging global evidence demonstrates marked interindividual differences in postprandial glucose response (PPGR) although no such data exists in India and previous studies have primarily evaluated PPGR variation in individuals without diabetes.
View Article and Find Full Text PDFThird Proceedings of The North American Airway Collaborative (NoAAC): Consensus Statement on Trial Design for Airway Stenosis.
JAMA Otolaryngol Head Neck Surg
January 2025
Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Importance: Airway stenosis is a rare but debilitating disorder that significantly degrades the quality of life in affected patients. Treatments are primarily surgical, and disease management lacks established medical therapies. The North American Airway Collaborative held its third symposium at The Johns Hopkins Hospital in Baltimore, Maryland, on April 15, 2024, focused on strategies to advance the care of these patients.
View Article and Find Full Text PDFInflammation and Occlusive Retinal Vasculitis Post Faricimab.
JAMA Ophthalmol
January 2025
Truhlsen Eye Center, Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha.
Importance: Randomized clinical trials have shown the safety and efficacy of faricimab as a novel vascular endothelial growth factor and angiopoietin-2 inhibitor in the treatment of neovascular age-related macular degeneration (nAMD) and macular edema of various etiologies. However, more rare adverse events may not be considered in clinical trials.
Objective: To describe 3 eyes that developed irreversible vision loss following initial mild intraocular inflammation (IOI) to faricimab.
Baseline Fasting Glucose Level, Age, Sex, and Body Mass Index and the Development of Diabetes in US Adults.
JAMA Netw Open
January 2025
Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic, Rochester, Minnesota.
Importance: Understanding the interplay between diabetes risk factors and diabetes development is important to develop individual, practice, and population-level prevention strategies.
Objective: To evaluate the progression from normal and impaired fasting glucose levels to diabetes among adults.
Design, Setting, And Participants: This retrospective community-based cohort study used data from the Rochester Epidemiology Project, in Olmsted County, Minnesota, on 44 992 individuals with at least 2 fasting plasma glucose (FPG) measurements from January 1, 2005, to December 31, 2017.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!